# TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

> **NCT05343013** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** TAS-102

## Key facts

- **NCT ID:** NCT05343013
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-06
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-05-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05343013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05343013, "TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05343013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*